Cytonome competitors

I am the Chief Executive Officer, President and Chairman of Abiomed, Inc. (NASDAQ: ABMD), the only medical device company focused solely on heart recovery. At Abiomed, we are driven by our four principles: recovering hearts and saving lives, leading in technology and innovation, growing shareholder value and sustaining a winning culture of putting patients first. As a U.S. military veteran, I also serve as Co-Founder and Chairman of the Mentoring Veterans Program (MVPvets), a nonprofit organization committed to helping military veterans network with industry mentors to discover career opportunities in the life sciences industry.

Mark Toland is a Chief Executive Officer at MMI S.p.A., Partner and EIR at BioStar Capital, and Chairman at Corindus Vascular Robotics Inc and is based in Boston, Massachusetts. He has worked as Senior VP:Corporate Accounts at Boston Scientific, President and CEO at Corindus Vascular Robotics Inc, and Sales Representative at Wallace Computer Services. Mark attended University of Louisville between 1987 and 1991.

Renold has over 20 years of experience in pharmaceutical research and development. He is an expert in polychromatic flow cytometry, cell sorting and immunology-based assay development. Prior to establishing FlowMetric, Renold worked for over 13 years at Centocor, a subsidiary of Johnson and Johnson. He established the polychromatic flow facility at Centocor to perform polychromatic flow cytometry and cell sorting. His work at Centocor earned him five prestigious Johnson & Johnson awards for scientific excellence and innovation. He has worked on marketed compounds, Remicade® and Stelara®. Ren has authored more than 30 peer reviewed scientific manuscripts and publications. He is co-author of one US Patent and has been invited to speak at International Conferences. He has also co-authored a chapter on the “Application of Flow Cytometry in Drug Development” for Immunotoxicology Strategies for Pharmaceutical Safety Assessment, published by John Wiley & Sons in August 2008.

Cynthia Bamdad is a CEO at Minerva Biotechnologies and is based in Boston, Massachusetts. She has worked as Director at Pharmacyclics and CSO Clinical Micro Sensors, now Genmark at Minerva Biotechnologies. Cynthia works or has worked as BOARD MEMBER at Schl of Social Science, BOARD MEMBER at Urban Affairs and Public Policy, and BOARD MEMBER at Northeastern University. She attended Harvard University between 1992 and 1997 and Northeastern University.